Plas-free

Executive Summary

Plas-free is an Israeli med-tech company developing affinity-based plasma filtration devices for critical care indications. Their lead product, ClearPlasma, is CE-marked for selective removal of plasminogen to treat massive bleeding, while the AAPC-300 system targets hepatic encephalopathy by removing ammonia. The technology offers a rapid, non-pharmacologic approach to conditions with high unmet medical need. Both devices have received CE marking, enabling commercialization in Europe, though the company remains in preclinical stages with limited publicly available financial data. Despite the early stage, the proprietary affinity platform and regulatory progress position Plas-free as a compelling player in hemostasis and liver disease management. Near-term revenue is uncertain, but the technology's differentiation and existing regulatory approvals mitigate some development risk.

Upcoming Catalysts (preview)

• H1 2027FDA 510(k) submission for ClearPlasma70% success
• Q4 2026Initial clinical results from compassionate use of AAPC-30050% success
• Q3 2026Strategic partnership or distribution agreement for European markets60% success